MetaVia Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 13, 2026, disclosing balance sheet and capital structure data for the quarter.

Key Highlights

  • Shares outstanding: As of November 9, 2026, the company had 6,742,889 shares of common stock, $0.001 par value, issued and outstanding.
  • Cash position: Cash and cash equivalents stood at $8,778 thousand as of September 30, 2026, down from $10,278 thousand as of December 31, 2025.
  • Total assets: Total assets were $9,554 thousand as of September 30, 2026, compared to $11,123 thousand as of December 31, 2025.
  • Total liabilities: Total liabilities increased to $7,143 thousand as of September 30, 2026, from $5,790 thousand as of December 31, 2025.
  • Clinical trial accrued liabilities: This line item rose to $1,579 thousand from $79 thousand at year-end 2025, according to the filing.
  • Related party payable: The related party payable declined to $2,119 thousand from $3,312 thousand at December 31, 2025.

MetaVia's Balance Sheet Shifts Between December 2025 and September 2026

MetaVia Inc. (NASDAQ:MTVA), a Delaware-incorporated company headquartered at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing identifies the company as a non-accelerated filer and a smaller reporting company, and confirms it is not a shell company.

According to the filing, total current assets decreased to $9,353 thousand from $10,875 thousand at December 31, 2025, driven primarily by the reduction in cash and cash equivalents. Total current liabilities rose to $7,060 thousand from $5,648 thousand over the same period. The increase in current liabilities was partly attributable to accounts payable growing to $2,478 thousand from $1,060 thousand, and clinical trial accrued liabilities rising sharply to $1,579 thousand from $79 thousand. The company disclosed a related party payable to Dong-A ST Co., Ltd., described in the filing as a related party, which fell from $3,312 thousand to $2,119 thousand.

The company's common stock share count rose substantially, with 6,742,889 shares issued and outstanding as of both September 30, 2026 and November 9, 2026, compared to 2,308,294 shares as of December 31, 2025. The filing notes that preferred stock - authorized at 10,000,000 shares - had no shares issued or outstanding at either balance sheet date. The filing contains forward-looking statements, which the company states are subject to its cautionary language and the risks described in the report and in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

What Was Disclosed

MetaVia Inc. submitted a quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated balance sheet data, share counts, and capital structure details, including changes in cash, liabilities, and stockholders' equity relative to December 31, 2025.